


# COVID-19 Vaccine Algorithm



APhA COVID-19 RESOURCES:  
KNOW THE FACTS

## START HERE



**Table 1: Definition of Moderately or Severely Immunocompromised Individuals**

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm<sup>3</sup>, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
- Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory.

**Table 2: COVID-19 Vaccine Options**

Vaccine Product	Vial Cap Color	Dose	Dilution Requirement	Age Requirement
<b>Pfizer-BioNTech</b>	<b>Purple</b>	0.3 mL (30 mcg)	Dilute w/ 1.8 mL 0.9% Sodium Chloride Inj.	≥12 years
<b>Pfizer-BioNTech</b>	<b>Gray</b>	0.3 mL (30 mcg)	Do NOT dilute	≥12 years
<b>Pfizer-BioNTech</b>	<b>Orange</b>	0.2 mL (10 mcg)	Dilute w/ 1.3 mL 0.9% Sodium Chloride Inj.	5-11 years
<b>Moderna</b>	<b>Red</b>	Primary / additional: 0.5 mL (100 mcg) Booster: 0.25mL (50 mcg)	Do NOT dilute	≥18 years
<b>Janssen (J&amp;J)</b>	<b>Blue</b>	0.5 mL (5x10 <sup>10</sup> viral particles)	Do NOT dilute	≥18 years

\*As of 12/23/21 the Pfizer-BioNTech COVID-19 vaccine with a purple cap requiring dilution will be retired. The Pfizer-BioNTech COVID-19 vaccine will now have a grey cap and does not require dilution. Patients who received a dose(s) of the purple cap product can receive the grey cap product for future doses.

\*\*Pfizer-BioNTech and Moderna COVID-19 vaccines are preferentially recommended in most situations compared to Janssen (J&J) COVID-19 vaccine, the Janssen (J&J) vaccine may be considered in some situations.

Reference CDC's [Clinical Considerations for Use of COVID-19 Vaccines](#) for detailed information.

**Disclaimer:** The information in this document is provided only for general informational purposes and does not constitute business or legal advice. Information related to the COVID-19 pandemic is changing rapidly and continuously. The material and information contained in this publication is believed to be current as of the date included on this document. The American Pharmacists Association assumes no responsibility for the accuracy, timeliness, errors, or omission contained herein. Links to any sources do not constitute any endorsement of, validity, or warranty of the information contained on any site. The user of these materials should not under any circumstances solely rely on, or act based on this publication. Pharmacy professionals retain the responsibility for using their own professional judgment and practicing in accordance with all rules, regulations, and laws governing the pharmacy practice within their jurisdiction.